Table 2. Statistical comparisons of lesion treatment effectiveness.
Control | New Base Placebo | New Base + Amoxi | Base 2b Placebo | Base 2b + Amoxi | |
---|---|---|---|---|---|
CNAT | |||||
Effective: ineffective | 0:8 (0%) | 0:2 (0%) | 2:5 (29%) | 3:5 (38%) | 2:1 (67%) |
Control | – | N/A (both zero) | 0.2 | 0.2 | 0.055 |
New Base Placebo | N/A (both zero) | – | 1 | 1 | 0.4 |
New Base + Amoxi | 0.2 | 1 | – | 1 | 0.5 |
Base 2b Placebo | 0.2 | 1 | 1 | – | 0.54 |
Base 2b + Amoxi | 0.055 | 0.4 | 0.5 | 0.54 | – |
OFAV | |||||
Effective: ineffective | 0:4 (0%) | 1:18 (5%) | 10:2 (83%) | 0:14 (0%) | 21:2 (91%) |
Control | – | 1 | 0.008 | N/A (both zero) | <0.001 |
New Base Placebo | 1 | – | <0.001 | 1 | <0.001 |
New Base + Amoxi | 0.008 | <0.001 | – | <0.001 | 0.594 |
Base 2b Placebo | N/A (both zero) | 1 | <0.001 | – | <0.001 |
Base 2b + Amoxi | <0.001 | <0.001 | 0.594 | <0.001 | – |
MCAV | |||||
Effective: ineffective | 0:4 (0%) | 0:6 (0%) | 4:0 (100%) | 0:9 (0%) | 8:1 (89%) |
Control | – | N/A (both zero) | 0.029 | N/A (both zero) | 0.007 |
New Base Placebo | N/A (both zero) | – | 0.005 | N/A (both zero) | 0.001 |
New Base + Amoxi | 0.029 | 0.005 | – | 0.001 | 1 |
Base 2b Placebo | N/A (both zero) | N/A (both zero) | 0.001 | – | <0.001 |
Base 2b + Amoxi | 0.007 | 0.001 | 1 | <0.001 | – |
DLAB | |||||
Effective: ineffective | – | – | – | 1:7 (13%) | 7:1 (88%) |
Base 2b Placebo | – | – | – | – | 0.001 |
PSTR | |||||
Effective: ineffective | – | – | – | 0:8 (0%) | 11:4 (73%) |
Base 2b Placebo | – | – | – | – | 0.001 |